project id: TCGA-PRAD; case submitter id: TCGA-EJ-A65G; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.25; rna integrity number: 8.2; age at index: 57; days to birth: -20821; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1955; age at diagnosis: 20821; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 666.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 299; initial weight: 140.0; sample id: 5706ad0b-6d7f-45b3-b6cf-e2d766fec9a9; sample submitter id: TCGA-EJ-A65G-01A; portion id: 7b5100e6-8656-42f2-971e-3ecc9aeb0b3f; portion submitter id: TCGA-EJ-A65G-01A-21; slide id: 5621ca0e-5a09-4709-bdb1-3e45599411f2; slide submitter id: TCGA-EJ-A65G-01A-02-TSB; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 95.0; section location: TOP;